Who can benefit more from its twelve-week treatment: A prospective cohort study of blonanserin for patients with schizophrenia

Table 4 Multivariate analysis of the influencing factors of brief psychiatric rating scale score reduction in general population

Characteristic	β	95%CI	P value
Current episode duration (month)	-0.03	-0.05 to -0.01	< 0.001
Whether in acute phase
No	0.00	N/A	N/A
Yes	5.42	4.0 to 6.9	< 0.001
Previous episodes	-0.22	-0.41 to -0.03	0.024
Baseline BPRS score	0.51	0.47 to 0.56	< 0.001
Mean daily dose of concomitant anti-psychiatrics1	-0.01	-0.01 to 0.00	< 0.001
Number of types of sedative-hypnotic agents	-1.22	-2.00 to -0.44	0.002

¹Chlorpromazine equivalent dose.

CI: Confidence interval; BPRS: Brief psychiatric rating scale; N/A: Not applicable.